[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017013072A - Inhibidores de grelina o-aciltransferasa. - Google Patents

Inhibidores de grelina o-aciltransferasa.

Info

Publication number
MX2017013072A
MX2017013072A MX2017013072A MX2017013072A MX2017013072A MX 2017013072 A MX2017013072 A MX 2017013072A MX 2017013072 A MX2017013072 A MX 2017013072A MX 2017013072 A MX2017013072 A MX 2017013072A MX 2017013072 A MX2017013072 A MX 2017013072A
Authority
MX
Mexico
Prior art keywords
ghrelin
transferase inhibitors
acyl transferase
inhibitors
acyl
Prior art date
Application number
MX2017013072A
Other languages
English (en)
Inventor
James Hembre Erik
Stanley Galka Christopher
Allan Honigschmidt Nicholas
Jo Keding Stacy
Angeles Martinez Grau Maria
Ruano Plaza Gema
Rubio Almudena
Lynn Smith Daryl
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017013072A publication Critical patent/MX2017013072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona nuevos inhibidores de GOAT y sus sales y composiciones farmacéuticas.
MX2017013072A 2015-04-15 2016-04-13 Inhibidores de grelina o-aciltransferasa. MX2017013072A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382182 2015-04-15
PCT/US2016/027180 WO2016168225A1 (en) 2015-04-15 2016-04-13 Ghrelin o-acyl transferase inhibitors

Publications (1)

Publication Number Publication Date
MX2017013072A true MX2017013072A (es) 2017-12-04

Family

ID=52991670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013072A MX2017013072A (es) 2015-04-15 2016-04-13 Inhibidores de grelina o-aciltransferasa.

Country Status (16)

Country Link
US (1) US10227310B2 (es)
EP (1) EP3283474B1 (es)
JP (1) JP6462151B2 (es)
KR (1) KR20170123694A (es)
CN (1) CN107454898B (es)
AR (1) AR104673A1 (es)
AU (1) AU2016247964A1 (es)
BR (1) BR112017018342A2 (es)
CA (1) CA2977837A1 (es)
EA (1) EA201792000A1 (es)
ES (1) ES2773994T3 (es)
IL (1) IL254021A0 (es)
MX (1) MX2017013072A (es)
TW (1) TWI592407B (es)
WO (1) WO2016168225A1 (es)
ZA (1) ZA201705678B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001427A (es) 2016-08-05 2019-06-10 Boehringer Ingelheim Int Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat).
JOP20200187A1 (ar) 2018-02-02 2020-07-29 Boehringer Ingelheim Int مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
CN111630055B (zh) 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
KR20200118124A (ko) 2018-02-02 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 그렐린 o-아실 트랜스퍼라제(goat) 억제제로 사용하기 위한 헤테로사이클릴-치환된 옥사디아졸로피리딘 유도체
AU2019215707A1 (en) 2018-02-02 2020-07-09 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors
PL4153599T3 (pl) 2020-05-22 2024-07-15 Boehringer Ingelheim International Gmbh Sposób wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4-b]pirydynokarboksylanu alkilu
EP4153600B1 (en) 2020-05-22 2024-08-07 Boehringer Ingelheim International GmbH Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670827A2 (en) 2003-09-05 2006-06-21 Eli Lilly And Company Anti-ghrelin antibodies
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
KR20070034583A (ko) 2004-07-14 2007-03-28 일라이 릴리 앤드 캄파니 항-그렐린 항체
EP1814916A2 (en) 2004-11-15 2007-08-08 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
US7479271B2 (en) 2005-02-23 2009-01-20 Eli Lilly And Company Humanized anti-ghrelin antibodies
JP6106179B2 (ja) 2012-02-24 2017-03-29 武田薬品工業株式会社 芳香環化合物
UA118034C2 (uk) 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази

Also Published As

Publication number Publication date
AU2016247964A1 (en) 2017-09-14
IL254021A0 (en) 2017-10-31
EP3283474A1 (en) 2018-02-21
WO2016168225A1 (en) 2016-10-20
ZA201705678B (en) 2019-07-31
TWI592407B (zh) 2017-07-21
CN107454898B (zh) 2020-05-05
TW201710249A (zh) 2017-03-16
US10227310B2 (en) 2019-03-12
JP2018511632A (ja) 2018-04-26
ES2773994T3 (es) 2020-07-16
AR104673A1 (es) 2017-08-09
KR20170123694A (ko) 2017-11-08
EA201792000A1 (ru) 2018-02-28
EP3283474B1 (en) 2019-12-18
BR112017018342A2 (pt) 2018-04-17
CN107454898A (zh) 2017-12-08
CA2977837A1 (en) 2016-10-20
JP6462151B2 (ja) 2019-01-30
US20180079729A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
PH12016500895B1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
GEP20217239B (en) Pharmaceutical composition
MX2017013073A (es) Inhibidores de grelina o-aciltransferasa.
MX2017013072A (es) Inhibidores de grelina o-aciltransferasa.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
GEP20217240B (en) Pharmaceutical composition
PH12017502028A1 (en) Vortioxetine pyroglutamate
PH12018500504A1 (en) Compounds useful for inhibiting ror-gamma-t
HUE054928T2 (hu) Oxadiazolopiridin-származékok ghrelin O-aciltranszferáz (GOAT)-inhibitorokként törtenõ alkalmazásra
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
MY188169A (en) Pharmaceutical compositions and use thereof
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
AU360128S (en) Adjustable label tie